| Identification | Back Directory | [Name]
Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)- | [CAS]
830346-47-9 | [Synonyms]
Elagolix Impurity 27
elagolix intermediate
elagolix intermediate 4
Elagolix Sodium Intermediate
4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-
1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimi
1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimid
1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,...
Benzeneacetic acid, 4-fluoro-.alpha.-(1-ethylethyl)-,(.alpha.S)-
Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)-
1-(2-Fluoro-6-trifluoromethyl-benzyl)-6-methyl-1H-pyrimidine-2,4-dione
1-[2-Fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione
1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione
1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methylpyrimidine-2,4-dione
1-(2-Flouro-6-(triflouromethyl)benzyl)-6-methylpyrimidine-2,4-(1H,3H)-dione
1-[2-Fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-
2-2,4(1H,3H)-dione
1-{2- Fluoro -6- trifluoromethyl - benzyl )-6- mcthyl -1H- pyrimidine -2,4- dione
1-[[2-Fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione
2,4(1H,3H)-Pyrimidinedione, 1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-
1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-6-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione | [Molecular Formula]
C13H10F4N2O2 | [MDL Number]
MFCD00792491 | [MOL File]
830346-47-9.mol | [Molecular Weight]
302.22 |
| Chemical Properties | Back Directory | [density ]
1.413±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [pka]
9.49±0.40(Predicted) | [InChI]
InChI=1S/C13H10F4N2O2/c1-7-5-11(20)18-12(21)19(7)6-8-9(13(15,16)17)3-2-4-10(8)14/h2-5H,6H2,1H3,(H,18,20,21) | [InChIKey]
IJRKKZXPXBTHER-UHFFFAOYSA-N | [SMILES]
C1(=O)N(CC2=C(C(F)(F)F)C=CC=C2F)C(C)=CC(=O)N1 |
| Hazard Information | Back Directory | [Uses]
1-(2-Fluoro-6-(trifluoromethyl)benzyl)-6-methylpyrimidine-2,4(1H,3H)-dione is a pharmaceutical intermediate ingredient used in the preparation of Elagolix sodium, which is FDA-approved for the treatment of pain associated with moderate to severe pain associated with endometriosis. |
|
|